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standard treatment alone. Mortality parameter was the most influential parameter 
on ICER. According to willingness-to-pay of Thailand, of approximately $3,861 per 
QALY gained, the probability of IVIG being cost-effective was 28%. ConClusions: 
The addition of IVIG to standard treatment in the treatment of childhood ITP with 
life threatening bleeding is a cost-effective intervention in Thailand. This evidence 
supported the decision-making that IVIG should be included in the health-benefit 
package as the first-line therapy of childhood ITP with life threatening bleeding.
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objeCtives: Published cost-effectiveness evidence on the various treatments used 
for relapsed or relapsed and refractory multiple myeloma (R or RRMM) has not been 
explored in a systematic literature review (SLR). We therefore investigated this topic 
using such an approach. Methods: We searched MEDLINE, EMBASE, The Cochrane 
Library and EconLit databases for English-language economic evaluations of pharma-
ceuticals for directly managing R or RRMM published after 2003. Publication quality 
was assessed using standard Drummond criteria. Results: Overall, 14 publications 
on nine primary economic models met the inclusion criteria. These involved com-
parisons between lenalidomide + dexamethasone and dexamethasone (n= 3) and 
between lenalidomide +/- dexamethasone and bortezomib (n= 7), of which some 
compared all these options (n= 2); and between bortezomib and best supportive care 
(n= 1). The studies varied in their geographical focus and economic perspective and, 
accordingly, the willingness-to-pay thresholds used. Bortezomib was cost-effective 
compared with dexamethasone in Sweden (moderate-quality study) and the UK 
(UK; abstract-only data), but neither study reported the perspective used. From a UK 
payer’s perspective, lenalidomide + dexamethasone was cost-effective compared 
to dexamethasone (but only 50% of the time in a probabilistic sensitivity analysis). 
Comparisons between lenalidomide + dexamethasone and bortezomib had varied 
results. Lenalidomide was dominant to bortezomib in a model for Russia (abstract-
only data) and lenalidomide + dexamethasone was cost-effective compared with 
bortezomib in studies for Portugal (societal perspective; abstract-only data), Greece 
(payer’s perspective; high-quality study) and Norway (payer’s perspective; moderate-
quality study). However, bortezomib was dominant to lenalidomide + dexamethasone 
in evaluations for Sweden (moderate-quality study) and the UK (abstract-only data), 
with neither clearly reporting the perspective used. ConClusions: The published 
cost-effectiveness evidence on lenalidomide versus bortezomib – the two most com-
monly used drugs for R or RRMM – is inconsistent. Our review suggests that none of 
the drugs available for this population represent an economically dominant option.
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objeCtives: Pharmacogenomic testing can be used to identify ultrarapid metabo-
lizers (UM) of codeine to ensure safe drug dosing in breastfeeding women. The 
objective of the study was to determine the incremental costs of genotyping in 
averting neonatal adverse events during maternal pharmacotherapy. Methods: 
We performed a cost effectiveness analysis to determine the incremental costs 
of genotyping to guide codeine use compared to standard care per infant adverse 
event averted . The base case was a prenatal patient whose metabolizer status was 
unknown but who may need to be prescribed codeine-containing analgesics for 
pain relief after delivery and planned to breast feed her child. Parameter estimates 
and costs were ascertained from a concurrent clinical study, from the literature and 
expert opinion. Results: Genetic testing to guide pharmacotherapy for maternal 
analgesia resulted in a cost of $3400 per adverse event averted or $740 per infant 
symptom day averted, when compared to standard care. The results were not sen-
sitive to a number of key variables in one way analysis, namely, cost of genetic 
testing and the probability of UM in the population. The results were sensitive to 
the probability of codeine use in the population and the costs of a hospital admis-
sion. This study was limited by a small number of trials from which parameter 
estimates could be extracted and the very small number of adverse events reported 
in infants. ConClusions: Although genotyping to guide pharmacotherapy was 
not cost saving, the cost to avert an infant adverse event may represent good value 
for money. It is not yet known whether implementation would be feasible, how-
ever these findings will have implications for new mothers and their health care 
providers world-wide.
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objeCtives: Neuropathic pain (NeP) affects more than 75% of the spinal cord injury 
(SCI) patients. Nearly half of the SCI patients in the United States were prescribed 
gabapentin for management of NeP even though gabapentin is not indicated for 
NeP. Pregabalin is indicated for NeP in the UK and United States, but only 16% of the 
SCI patients in the United States were prescribed pregabalin. This study evaluates 
cost-effectiveness of pregabalin and gabapentin in management of NeP from the 
societal perspective. Methods: We have used a Markov model to simulate costs 
and effectiveness for 1,000 patients treated with placebo, pregabalin and gabapentin 
over a 5-year period with a monthly cycle. Transition probabilities for placebo and 
pregabalin were estimated based on a double-blind, randomized controlled trial. 
High-quality clinical data for gabapentin effectiveness is not available and thus 
fairly substantial. The postoperative cost over 48 hours is slightly higher for abdominal 
surgeries compared to THA or TKA.
PSY25
ecOnOmic evALuAtiOn Of PrOPhYLActic treAtment vS On demAnd fOr 
mOderAte hemOPhiLiA A in cOLOmbiA
Ordoñez Molina JE1, Duque JG1, Gutierrez-Ardila MV2
1HEMOGROUP Hematoncology Medical Center, Medellín, Colombia, 2Pfizer S.A.S., Bogotá, 
Colombia
objeCtives: Hemophilia A is a genetic disease in which there is a deficiency in the 
level of activity of the clotting factor VIII, the moderate form is defined as a blood 
clotting factor level from 0.01 to 0.05 IU/ml. The aim of this analysis is to estimate the 
cost-effectiveness of prophylactic treatment of moderate hemophilia A compared to 
demand treatment in Colombia. Methods: A decision tree model was developed 
using a life expectancy horizon and a societal perspective; annual discount rate of 
3% was applied to costs and effectiveness measures. Prophylactic treatment with 
recombinant factor VIII (25 IU/kg 3 times per week) was compared to on demand 
treatment (40 IU/kg BID for 3.5 days for each bleeding episode). The base case was 
simulated based on a patient of 8 years old and weight of 31kg without inhibitors. 
Effectiveness and probabilities of adverse events were taken from the literature. 
Costs (direct and indirect) were taken from local tariff manuals (SOAT and SISMED). 
Effectiveness measures were number of cases avoided of bleeding, hemarthrosis and 
arthropathies. All data were validated with a clinical expert. Univariate sensitivity 
analysis was done. Costs are presented in 2013 USD (exchange rate US$1 = $ 1927 
COP). Results: Over the time horizon, prophylactic treatment avoids 277 episodes 
of bleeding and 23 of joint damage. Total expected costs with prophylactic treatment 
were US$ 2.7M compared to on demand treatment US$ 2.4M. The incremental cost 
effectiveness ratios (ICER) for prophylactic treatment were US$ 1,056/avoided bleeding 
and US$12,512/avoided hemarthrosis/arthropathies. Sensitivity analysis showed the 
robustness of the results (average ICER US$ 1,153/avoided bleeding). ConClusions: 
From the social perspective, prophylactic treatment of moderate hemophilia A, with 
recombinant factor VIII would be a highly cost-effectiveness intervention with strong 
health benefits in number of cases of bleeding and joint damage avoided.
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objeCtives: Hemophilia B is a genetic disease characterized by a defect in coagula-
tion factor IX, needed for this function. Moderate hemophilia is defined as a blood 
clotting factor level from 1 to 5 % of normal, some people from this group, can have 
bleeding similar to people with severe hemophilia; most of them, has one bleeding 
episode monthly. This analysis is aimed to estimate the cost-effectiveness of pro-
phylactic treatment of moderate hemophilia B, compared to on demand treatment 
in Colombia. Methods: A decision tree model was developed using a time horizon 
of life expectancy. A societal perspective was adopted, and an annual discount rate 
of 3% was applied to costs and effectiveness measures. Prophylactic treatment with 
recombinant factor IX (25 IU/kg 3 times per week) was compared to on demand treat-
ment (40 IU/kg BID for 4.5 days for each bleeding episode). Simulation of base case 
was applied for a patient of 10 years, weight of 37 kg without inhibitors. Effectiveness 
and probabilities of adverse events were taken from a literature. Costs (direct and 
indirect) were taken from local tariff manuals (SOAT and SISMED). Costs are pre-
sented in 2013 US$ (1$ USD = $ 1 927 COP). Effectiveness measures were number of 
cases avoided of bleeding, hemarthrosis and arthropathy. All data were validated 
with a clinical expert. Univariate sensitivity analysis was done. Results: Over the 
time horizon, prophylactic treatment avoids 275 episodes of bleeding and 23 of joint 
damage. Total expected costs with prophylactic treatment were US$ 7.4M compared 
to on demand treatment US$ 8.2M, generating savings of US$ 870,778. Sensitivity 
analysis showed the robustness of the results (99.3 % dominant) ConClusions: 
Prophylactic treatment of moderate hemophilia B, with recombinant factor IX would 
be a cost-saving intervention from the social perspective.
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objeCtives: Although the international guideline recommended intravenous 
immunoglobulin (IVIG) as the first-line treatment for childhood idiopathic throm-
bocytopenia purpura (ITP) with life threatening bleeding, ITP patients may not be 
able to access IVIG due to the limitation of health benefit packages especially those 
in developing countries. There remains an important policy question whether IVIG 
used as first-line treatment is worth the money spent. Thus, the objective of this 
study is to perform the cost-effectiveness analysis of adding IVIG to standard treat-
ment of platelet transfusion and corticosteroid, for the treatment of childhood ITP 
with life threatening bleeding. Methods: A cost- effectiveness analysis using a 
hybrid model consisting of a decision tree and Markov models was conducted under 
societal perspective. The effectiveness and utility parameters were determined by 
systematic reviews, while costs and mortality parameters were determined using 
retrospective electronic hospital database analysis. The discount rate of 3% was 
applied for both costs and outcomes. One-way and probabilistic sensitivity analyses 
were also performed. Results: The incremental cost-effectiveness ratio (ICER) was 
$ 2,063 per quality-adjusted life year gained ($/QALY) for the addition of IVIG versus 
